‘New Era’ To Begin For UK’s ILAP In 2025, With Focus On ‘Transformative’ Drugs

Some stakeholders say that the entry criteria for the licensing and access pathway have been too broad, leading to an overburdening of the scheme.

Transformation origami figures
The UK wants to encourage the development of "transformative" medicines (Shutterstock)

More from Agency Leadership

More from Pathways & Standards